Please enable JavaScript.
Coggle requires JavaScript to display documents.
Guillain-Barré Syndrome (GBS) - Coggle Diagram
Guillain-Barré Syndrome (GBS)
Definition and Overview
Guillain-Barré Syndrome (GBS) is an acute inflammatory demyelinating polyneuropathy that affects the peripheral nervous system. It leads to progressive motor weakness and areflexia (loss of reflexes). GBS is a medical emergency due to its potential to cause respiratory failure and autonomic dysfunction.
Etiology and Triggers
The exact cause is unknown, but GBS is often preceded by an infection. Common triggers include:
Campylobacter jejuni (most common bacterial trigger)
Viral infections like Epstein-Barr virus, CMV, and HIV
Post-surgical states
Vaccinations (rarely)
The disease is thought to be immune-mediated, where the body's immune response damages the myelin sheath or axons of peripheral nerves.
Pathophysiology
GBS involves an autoimmune attack on the myelin sheath or axon of peripheral nerves. This results in nerve conduction blocks, leading to muscle weakness and paralysis. In some forms, the immune system attacks the axon itself (e.g., AMAN variant), leading to more severe damage.
Types of Guillain-Barré Syndrome
AIDP (Acute Inflammatory Demyelinating Polyradiculoneuropathy): Most common form; mainly affects myelin.
AMAN (Acute Motor Axonal Neuropathy): More severe; affects axons directly.
AMSAN (Acute Motor-Sensory Axonal Neuropathy): Affects both motor and sensory axons.
Miller Fisher Syndrome: Presents with ataxia, areflexia, and ophthalmoplegia.
Clinical Manifestations
Symptoms typically begin in the lower extremities and ascend upward (ascending paralysis). Key symptoms include:
Symmetrical muscle weakness starting in legs
Areflexia (loss of deep tendon reflexes)
Paresthesia (tingling or numbness)
Facial weakness (in ~50% of cases)
Dysphagia and dysarthria
Autonomic disturbances: BP fluctuations, arrhythmias, sweating abnormalities
Diagnosis
Diagnosis is clinical but supported by tests:
Lumbar puncture: Elevated protein in cerebrospinal fluid (CSF) with normal WBC count (albuminocytologic dissociation)
Nerve conduction studies (NCS) and EMG: Show slowed conduction or axonal damage
MRI: May help exclude other diagnoses
Antibody testing: Anti-GQ1b antibodies for Miller Fisher Syndrome
Medical Management
Early and aggressive treatment is essential. Main therapies include:
IVIG (Intravenous Immunoglobulin): First-line therapy, started within first 2 weeks of symptoms
Plasmapheresis: Removes circulating antibodies; used if IVIG is not available or ineffective
Supportive care: Includes airway management, prevention of complications, and monitoring autonomic function
Nursing Management and Monitoring
Nursing responsibilities are critical, including:
Respiratory assessment: Monitor for respiratory muscle involvement; assess vital capacity
Airway support: May require mechanical ventilation
Pain management
Nutrition and hydration support
Skin care and DVT prophylaxis
Communication support if facial or bulbar muscles are involved
Complications
Common and serious complications include:
Respiratory failure
Autonomic instability: arrhythmias, hypertension, hypotension
Infections: due to immobility or ventilatory support
Deep vein thrombosis and pulmonary embolism
Pressure ulcers and contractures
Prognosis and Recovery
Prognosis varies: Most patients recover, but it can take weeks to months
About 80% regain full ambulation within 6 months
Around 5–10% may experience relapses or chronic issues
Early treatment and rehabilitation improve outcomes
Recovery occurs in reverse order: upper limbs and face recover before lower limbs